Related Experiment Videos
[Obesity pharmacological treatment]
J L Pereira Cunill1, R Astorga Jiménez
1Servicio de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla.
Revista Clinica Espanola
|April 30, 2005
Summary
Pharmacological obesity treatments, including sibutramine and orlistat, are increasingly important due to rising obesity rates. These medications should complement lifestyle changes for overweight and obese patients with comorbidities.
Area of Science:
- Clinical pharmacology
- Obesity medicine
Background:
- Growing incidence of obesity in Western countries necessitates advanced treatment strategies.
- Increased understanding of obesity's biological underpinnings fuels pharmacological research.
- Limitations of non-pharmacological interventions highlight the need for drug-based therapies.
Purpose of the Study:
- To summarize the current landscape of pharmacological obesity treatment.
- To outline the approved medications and their indications.
- To emphasize the role of pharmacotherapy within a comprehensive weight management plan.
Main Methods:
- Review of current clinical observations on obesity pharmacotherapy.
- Identification of drugs approved by regulatory agencies (European Medicines Agency, FDA).
- Analysis of patient criteria (BMI, comorbidities) for pharmacological intervention.
Main Results:
- Sibutramine and orlistat are the only two drugs currently approved for long-term obesity management.
- Pharmacological treatment is indicated for patients with a Body Mass Index (BMI) > 30 or BMI > 27 with comorbidities.
- Comorbidities include diabetes mellitus, hypertension, and dyslipidemias.
Conclusions:
- Pharmacological treatment is a valuable component of obesity management.
- Medications should be integrated with diet, exercise, and psychological support.
- Obesity pharmacotherapy should be considered for specific patient populations based on BMI and health status.